Report

  1. Home
  2. Discounted reports

Biosimilar Testing and Development Services Market By Type (Pharmacokinetics Assay, Immunogenicity Testing, Others), By End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Market Report I 2023-12-01 I 302 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The global biosimilar testing and development services market was valued at $ 2486.9 million in 2022 and is projected to reach $ 7807.7 million by 2032, registering a CAGR of 12.1% from 2023 to 2032.Biosimilar testing and development services are specialized services provided by companies, contract research organizations (CROs), or research institutions to support the development, approval, and commercialization of biosimilar products. Biosimilars are biologic drugs that are highly similar to an already approved biological product (reference product) in terms of quality, safety, and efficacy. Biologic drugs, unlike conventional pharmaceuticals, are manufactured using living cells and are typically more complex molecules, making them difficult to replicate exactly. However, biosimilars are developed to be as close as possible to the reference product and are intended to have no clinically meaningful differences in terms of safety and effectiveness.
The biosimilar testing and development services market is driven by rise in outsourcing of preclinical, clinical and laboratory testing services by pharma and biotech companies, and rise in need of biosimilar testing services to meet the growing demand for biosimilars for the treatment of chronic diseases.The biosimilar testing and development services market is expected to experience a significant surge due to the notable rise in outsourcing by pharmaceutical and biotech companies for preclinical, clinical, and laboratory testing services. Increasing pressure to bring cost-effective drugs to market has driven pharmaceutical and biotech firms to explore alternative strategies for biosimilar development. Outsourcing preclinical and clinical testing services to specialized providers offers a cost-efficient approach as compared to maintaining in-house facilities and capabilities. By doing so, companies can redirect their resources towards core R&D activities, enhancing their overall competitiveness in the industry. In addition, the complexity and stringent regulatory requirements associated with biosimilar development have necessitated the engagement of expert organizations that possess the necessary knowledge and experience. Outsourcing to established testing service providers allows pharmaceutical and biotech companies to tap into a vast pool of expertise, ensuring compliance with the strict regulatory guidelines governing biosimilar approval processes. The strategic approach has allowed these companies to streamline their operations, access specialized expertise and cutting-edge technologies, navigate complex regulatory requirements, and capitalize on the market for biosimilars. In conclusion, the rise in outsourcing of preclinical, clinical, and laboratory testing services by pharmaceutical and biotech companies has emerged as a pivotal driver for the biosimilar testing and development services market. Moreover, the rise in demand for biosimilars is expected to drive the growth of the biosimilar testing and development services market. The rise in demand for biosimilars is attributed to the cost-effectivity of the biosimilar as compared to its reference drug and the surge in prevalence of chronic diseases.
One of the key factors fueling the demand for biosimilars is the escalating burden of chronic diseases, such as cancer, autoimmune disorders, diabetes, and others. According to a study conducted by researchers at Oxford University, as of 2023, one in ten people has autoimmune disorders. As these conditions continue to afflict a large segment of the global population, there is a pressing need for affordable and accessible treatment options. Biosimilars have emerged as a compelling solution, presenting the same therapeutic effects as their originator counterparts but at reduced costs. This affordability aspect significantly expands patient access to crucial treatments, particularly in emerging economies where healthcare budgets may be constrained. According to U.S. Food and Drug Administration, as of May 2023, 41 biosimilars drugs are approved. These biosimilars are approved for the treatment of chronic disease such as rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PA), ankylosing spondylitis (AS), plaque psoriasis (PsO), inflammatory bowel disease (IBD), adult Crohn disease (CD), ulcerative colitis (UC), granulomatosis with polyangiitis (GPA) (Wegener granulomatosis), microscopic polyangiitis (MPA), type 1 diabetes mellitus (DM), non-squamous non-small cell lung cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, glioblastoma, recurrent or metastatic cervical cancer, HER2 (human epidermal growth factor receptor 2) associated breast cancer, HER2 associated gastric (metastatic) or gastroesophageal junction adenocarcinoma, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL).

In addition, biologicsdrugs, which are highly effective in treating various chronic and life-threatening diseases, often come with high price tags, making them inaccessible to a large segment of the population. However, biosimilars, which are comparable versions of reference biologics, present a promising solution to this problem. Biosimilar drugs undergo a rigorous development process to demonstrate dissimilarity to the reference product in terms of quality, safety, and efficacy. Once approved, biosimilars can offer significant cost savings as compared to the original biologic drugs. According to Association for Accessible Medicines (U.S.), in 2021, biosimilars generated $7 billion in savings for patients and the healthcare system. This cost advantage has the potential to drive healthcare expenditure, making essential treatments more accessible to patients while also reducing the financial burden on healthcare systems. Rise in demand for biosimilar product results in demand for services that facilitate the testing and development of biosimilars.
However, stringent regulatory requirements might act as a restraint for the growth of the market. However, patent expiration of biological drugs is expected to serve as a growth opportunity in the market.
The biosimilar testing and development services market is segmented on the basis of type and end user, and region. By type, the market is categorized into pharmacokinetics, immunogenicity, and others. The others include, ligand binding assay, biomarker, and stability testing. By end user, the market is categorized into pharmaceutical and biopharmaceutical companies, contract research organizations, and others. Others include contract development and manufacturing organization, independent lab, and regulatory bodies. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global biosimilar testing and development services market are Charles River Laboratories, Element Materials Technology, Intertek Group plc, Pacific biolabs, Inc, Profacgen Technologies Inc, Sartorius AG, SGS, BioPharmaSpec Ltd., Veeda Clinical Research Pvt. Ltd, and Eurofins Scientific SE.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimilar testing and development services market analysis from 2022 to 2032 to identify the prevailing biosimilar testing and development services market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the biosimilar testing and development services market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global biosimilar testing and development services market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Type
- Pharmacokinetics Assay
- Immunogenicity Testing
- Others
By End User
- Pharmaceutical and Biopharmaceutical Companies
- Contract Research Organizations
- Others
By Region
- North America
? U.S.
? Canada
? Mexico
- Europe
? Germany
? France
? UK
? Italy
? Spain
? Rest of Europe
- Asia-Pacific
? Japan
? China
? India
? Australia
? South Korea
? Rest of Asia-Pacific
- LAMEA
? Brazil
? Saudi Arabia
? South Africa
? Rest of LAMEA
- Key Market Players
? Sartorius AG
? Pacific Biolabs, Inc.
? BioPharmaSpec Ltd.
? Charles River Laboratories
? Intertek Group plc
? SGS
? Veeda Clinical Research Pvt. Ltd.
? Eurofins Scientific SE
? Profacgen Technologies Inc.
? Element Materials Technology

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in need of biosimilar testing facilities.
3.4.1.2. Rise in outsourcing of preclinical, clinical, and laboratory testing services by pharma and biotech companies
3.4.2. Restraints
3.4.2.1. Stringent regulatory requirements.
3.4.3. Opportunities
3.4.3.1. Patent expirations of biologic drugs.
CHAPTER 4: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Pharmacokinetics Assay
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Immunogenicity Testing
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical and Biopharmaceutical Companies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Contract Research Organizations
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. BioPharmaSpec Ltd.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.2. Charles River Laboratories
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Element Materials Technology
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.4. Eurofins Scientific SE
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Intertek Group plc
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Pacific Biolabs, Inc.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Key strategic moves and developments
8.7. Profacgen Technologies Inc.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.8. Sartorius AG
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. SGS
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Veeda Clinical Research Pvt. Ltd.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR PHARMACOKINETICS ASSAY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR IMMUNOGENICITY TESTING, BY REGION, 2022-2032 ($MILLION)
TABLE 04. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 06. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 10. NORTH AMERICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 11. NORTH AMERICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. NORTH AMERICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 13. U.S. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. U.S. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 15. CANADA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 16. CANADA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 17. MEXICO BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 18. MEXICO BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 20. EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 21. EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. GERMANY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. GERMANY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 24. FRANCE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 25. FRANCE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. UK BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. UK BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 28. ITALY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 29. ITALY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. SPAIN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 31. SPAIN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. REST OF EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 33. REST OF EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 34. ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 37. JAPAN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 38. JAPAN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. CHINA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. CHINA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. INDIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 42. INDIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 43. AUSTRALIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. AUSTRALIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. SOUTH KOREA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. SOUTH KOREA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 50. LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. BRAZIL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 53. BRAZIL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. SAUDI ARABIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. SAUDI ARABIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 56. SOUTH AFRICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 57. SOUTH AFRICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. REST OF LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. REST OF LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 60. BIOPHARMASPEC LTD.: KEY EXECUTIVES
TABLE 61. BIOPHARMASPEC LTD.: COMPANY SNAPSHOT
TABLE 62. BIOPHARMASPEC LTD.: SERVICE SEGMENTS
TABLE 63. BIOPHARMASPEC LTD.: PRODUCT PORTFOLIO
TABLE 64. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
TABLE 65. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 66. CHARLES RIVER LABORATORIES: PRODUCT SEGMENTS
TABLE 67. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
TABLE 68. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 69. ELEMENT MATERIALS TECHNOLOGY: KEY EXECUTIVES
TABLE 70. ELEMENT MATERIALS TECHNOLOGY: COMPANY SNAPSHOT
TABLE 71. ELEMENT MATERIALS TECHNOLOGY: SERVICE SEGMENTS
TABLE 72. ELEMENT MATERIALS TECHNOLOGY: PRODUCT PORTFOLIO
TABLE 73. EUROFINS SCIENTIFIC SE: KEY EXECUTIVES
TABLE 74. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
TABLE 75. EUROFINS SCIENTIFIC SE: SERVICE SEGMENTS
TABLE 76. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
TABLE 77. EUROFINS SCIENTIFIC SE: KEY STRATERGIES
TABLE 78. INTERTEK GROUP PLC: KEY EXECUTIVES
TABLE 79. INTERTEK GROUP PLC: COMPANY SNAPSHOT
TABLE 80. INTERTEK GROUP PLC: PRODUCT SEGMENTS
TABLE 81. INTERTEK GROUP PLC: SERVICE SEGMENTS
TABLE 82. INTERTEK GROUP PLC: PRODUCT PORTFOLIO
TABLE 83. PACIFIC BIOLABS, INC.: KEY EXECUTIVES
TABLE 84. PACIFIC BIOLABS, INC.: COMPANY SNAPSHOT
TABLE 85. PACIFIC BIOLABS, INC.: SERVICE SEGMENTS
TABLE 86. PACIFIC BIOLABS, INC.: PRODUCT PORTFOLIO
TABLE 87. PACIFIC BIOLABS, INC.: KEY STRATERGIES
TABLE 88. PROFACGEN TECHNOLOGIES INC.: KEY EXECUTIVES
TABLE 89. PROFACGEN TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 90. PROFACGEN TECHNOLOGIES INC.: PRODUCT SEGMENTS
TABLE 91. PROFACGEN TECHNOLOGIES INC.: SERVICE SEGMENTS
TABLE 92. PROFACGEN TECHNOLOGIES INC.: PRODUCT PORTFOLIO
TABLE 93. SARTORIUS AG: KEY EXECUTIVES
TABLE 94. SARTORIUS AG: COMPANY SNAPSHOT
TABLE 95. SARTORIUS AG: PRODUCT SEGMENTS
TABLE 96. SARTORIUS AG: PRODUCT PORTFOLIO
TABLE 97. SGS: KEY EXECUTIVES
TABLE 98. SGS: COMPANY SNAPSHOT
TABLE 99. SGS: PRODUCT SEGMENTS
TABLE 100. SGS: SERVICE SEGMENTS
TABLE 101. SGS: PRODUCT PORTFOLIO
TABLE 102. VEEDA CLINICAL RESEARCH PVT. LTD.: KEY EXECUTIVES
TABLE 103. VEEDA CLINICAL RESEARCH PVT. LTD.: COMPANY SNAPSHOT
TABLE 104. VEEDA CLINICAL RESEARCH PVT. LTD.: SERVICE SEGMENTS
TABLE 105. VEEDA CLINICAL RESEARCH PVT. LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES
FIGURE 01. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR PHARMACOKINETICS ASSAY, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR IMMUNOGENICITY TESTING, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET BY REGION, 2022 AND 2032(%)
FIGURE 20. U.S. BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 21. CANADA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 22. MEXICO BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 23. GERMANY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 24. FRANCE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 25. UK BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 26. ITALY BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 27. SPAIN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 28. REST OF EUROPE BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 29. JAPAN BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 30. CHINA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 31. INDIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 32. AUSTRALIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 33. SOUTH KOREA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF ASIA-PACIFIC BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 35. BRAZIL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 36. SAUDI ARABIA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH AFRICA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF LAMEA BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, 2022-2032 ($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR (2022-2023)
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2023)
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY (2022-2023)
FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43. COMPETITIVE DASHBOARD
FIGURE 44. COMPETITIVE HEATMAP: BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET
FIGURE 45. TOP PLAYER POSITIONING, 2022
FIGURE 46. CHARLES RIVER LABORATORIES: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 47. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 48. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. EUROFINS SCIENTIFIC SE: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. EUROFINS SCIENTIFIC SE: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. INTERTEK GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 52. INTERTEK GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 53. INTERTEK GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. SARTORIUS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 55. SARTORIUS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 56. SARTORIUS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 57. SGS: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 58. SGS: REVENUE SHARE BY SEGMENT, 2022 (%)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3456.00 $3110.40
  • $5730.00 $5157.00
  • $9600.00 $8640.00
  • ADD TO BASKET
  • BUY NOW